149 related articles for article (PubMed ID: 29881288)
41. Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence.
Zheng QS; Chen SH; Wu YP; Chen HJ; Chen H; Wei Y; Li XD; Huang JB; Xue XY; Xu N
J Cancer; 2018; 9(6):959-967. PubMed ID: 29581775
[No Abstract] [Full Text] [Related]
42. Leucine Zipper-EF-Hand Containing Transmembrane Protein 1 Is a Potential Prognostic Biomarker and Promotes Cell Progression in Prostate Cancer.
Piao L; Li H; Feng Y; Li X; Cui Y; Xuan Y
Cancer Manag Res; 2020; 12():1649-1660. PubMed ID: 32184668
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-335 acts as a candidate tumor suppressor in prostate cancer.
Xiong SW; Lin TX; Xu KW; Dong W; Ling XH; Jiang FN; Chen G; Zhong WD; Huang J
Pathol Oncol Res; 2013 Jul; 19(3):529-37. PubMed ID: 23456549
[TBL] [Abstract][Full Text] [Related]
44.
Cai C; Luo J; Liu Q; Liu Z; Zhao Y; Wu X; Yuegao Y; Lei Y; Lu J; Wang Y; Cai Z; Duan X; Lei M; Gu D; Liu Y
Genet Test Mol Biomarkers; 2021 Feb; 25(2):131-139. PubMed ID: 33596143
[No Abstract] [Full Text] [Related]
45. Enhanced expression of IMPDH2 promotes metastasis and advanced tumor progression in patients with prostate cancer.
Zhou L; Xia D; Zhu J; Chen Y; Chen G; Mo R; Zeng Y; Dai Q; He H; Liang Y; Jiang F; Zhong W
Clin Transl Oncol; 2014 Oct; 16(10):906-13. PubMed ID: 24659377
[TBL] [Abstract][Full Text] [Related]
46. Loss of miR-449a-caused PrLZ overexpression promotes prostate cancer metastasis.
Chen W; Liu Y; Chen H; Ning H; Ding K
Int J Oncol; 2017 Aug; 51(2):435-444. PubMed ID: 28627667
[TBL] [Abstract][Full Text] [Related]
47. Upregulation of Holliday junction recognition protein predicts poor prognosis and biochemical recurrence in patients with prostate cancer.
Chen YF; Liang YX; Yang JA; Yuan DZ; Li J; Zheng SS; Wan YP; Wang B; Han ZD; Zhong WD
Oncol Lett; 2019 Dec; 18(6):6697-6703. PubMed ID: 31814851
[TBL] [Abstract][Full Text] [Related]
48. βKlotho Inhibits Cell Proliferation by Downregulating ELK4 and Predicts Favorable Prognosis in Prostate Cancer.
Mao C; Dong W; Lu J; Zhang Z; Wu H; Ghavamian A; Bi D; Gao P; Liu Z; Ding S
Cancer Manag Res; 2021; 13():6377-6387. PubMed ID: 34408497
[TBL] [Abstract][Full Text] [Related]
49. Robo 4 - the double-edged sword in prostate cancer: impact on cancer cell aggressiveness and tumor vasculature.
Pircher A; Schäfer G; Eigentler A; Pichler R; Puhr M; Steiner E; Horninger W; Gunsilius E; Klocker H; Heidegger I
Int J Med Sci; 2019; 16(1):115-124. PubMed ID: 30662335
[No Abstract] [Full Text] [Related]
50. Overexpression of α (1,6) fucosyltransferase associated with aggressive prostate cancer.
Wang X; Chen J; Li QK; Peskoe SB; Zhang B; Choi C; Platz EA; Zhang H
Glycobiology; 2014 Oct; 24(10):935-44. PubMed ID: 24906821
[TBL] [Abstract][Full Text] [Related]
51. Overexpression levels of cripto-1 predict poor prognosis in patients with prostate cancer following radical prostatectomy.
Liu Y; Wang J; Yang T; Liu R; Xu Y
Oncol Lett; 2019 Sep; 18(3):2584-2591. PubMed ID: 31452743
[TBL] [Abstract][Full Text] [Related]
52. Periostin: a promising target of therapeutical intervention for prostate cancer.
Sun C; Zhao X; Xu K; Gong J; Liu W; Ding W; Gou Y; Xia G; Ding Q
J Transl Med; 2011 Jun; 9():99. PubMed ID: 21714934
[TBL] [Abstract][Full Text] [Related]
53. Acute Downregulation of Novel Hypothalamic Protein Sushi Repeat-Containing Protein X-Linked 2 after Experimental Traumatic Brain Injury.
Anwer M; Lara-Valderrabano L; Karttunen J; Ndode-Ekane XE; Puhakka N; Pitkänen A
J Neurotrauma; 2020 Apr; 37(7):924-938. PubMed ID: 31650880
[TBL] [Abstract][Full Text] [Related]
54. Prognostic value of transformer 2β expression in prostate cancer.
Diao Y; Wu D; Dai Z; Kang H; Wang Z; Wang X
Int J Clin Exp Pathol; 2015; 8(6):6967-73. PubMed ID: 26261585
[TBL] [Abstract][Full Text] [Related]
55. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
56. The metabolic role of PFKFB4 in androgen-independent growth in vitro and PFKFB4 expression in human prostate cancer tissue.
Li X; Chen Z; Li Z; Huang G; Lin J; Wei Q; Liang J; Li W
BMC Urol; 2020 Jun; 20(1):61. PubMed ID: 32487245
[TBL] [Abstract][Full Text] [Related]
57. Eukaryotic translation initiation factor 5A2 is highly expressed in prostate cancer and predicts poor prognosis.
Lu J; Zhao HW; Chen Y; Wei JH; Chen ZH; Feng ZH; Huang Y; Chen W; Luo JH; Fang Y
Exp Ther Med; 2019 May; 17(5):3741-3747. PubMed ID: 30988760
[TBL] [Abstract][Full Text] [Related]
58. Prognostic impact of NDRG2 and NDRG3 in prostate cancer patients undergoing radical prostatectomy.
Ren GF; Tang L; Yang AQ; Jiang WW; Huang YM
Histol Histopathol; 2014 Apr; 29(4):535-42. PubMed ID: 24222185
[TBL] [Abstract][Full Text] [Related]
59. Expression and clinical significance of the nin one binding protein and p38 MAPK in prostate carcinoma.
Che JP; Li W; Yan Y; Liu M; Wang GC; Li QY; Yang B; Yao XD; Zheng JH
Int J Clin Exp Pathol; 2013; 6(11):2300-11. PubMed ID: 24228091
[TBL] [Abstract][Full Text] [Related]
60. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
